- Home
- PIII vs ALXO Comparison
PIII vs ALXO Comparison
Compare PIII & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- ALXO
- Stock Information
- Founded
- PIII 2015
- ALXO 2015
- Country
- PIII United States
- ALXO United States
- Employees
- PIII N/A
- ALXO N/A
- Industry
- PIII Medical/Nursing Services
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- PIII Health Care
- ALXO Health Care
- Exchange
- PIII Nasdaq
- ALXO Nasdaq
- Market Cap
- PIII 21.4M
- ALXO 24.0M
- IPO Year
- PIII N/A
- ALXO 2020
- Fundamental
- Price
- PIII $6.16
- ALXO $0.44
- Analyst Decision
- PIII Buy
- ALXO Strong Buy
- Analyst Count
- PIII 2
- ALXO 6
- Target Price
- PIII $16.25
- ALXO $3.30
- AVG Volume (30 Days)
- PIII 5.2K
- ALXO 368.8K
- Earning Date
- PIII 08-06-2025
- ALXO 08-07-2025
- Dividend Yield
- PIII N/A
- ALXO N/A
- EPS Growth
- PIII N/A
- ALXO N/A
- EPS
- PIII N/A
- ALXO N/A
- Revenue
- PIII $1,485,192,000.00
- ALXO N/A
- Revenue This Year
- PIII N/A
- ALXO N/A
- Revenue Next Year
- PIII $6.01
- ALXO N/A
- P/E Ratio
- PIII N/A
- ALXO N/A
- Revenue Growth
- PIII 9.79
- ALXO N/A
- 52 Week Low
- PIII $6.00
- ALXO $0.41
- 52 Week High
- PIII $32.54
- ALXO $8.78
- Technical
- Relative Strength Index (RSI)
- PIII 33.55
- ALXO 40.22
- Support Level
- PIII $6.00
- ALXO $0.45
- Resistance Level
- PIII $6.35
- ALXO $0.53
- Average True Range (ATR)
- PIII 0.22
- ALXO 0.05
- MACD
- PIII 0.03
- ALXO -0.01
- Stochastic Oscillator
- PIII 21.62
- ALXO 4.98
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.